Capecitabine

Generic Name
Capecitabine
Brand Names
Ecansya, Xeloda, Capecitabine Medac, Ecansya (previously Capecitabine Krka), Capecitabine Accord, Capecitabine Teva
Drug Type
Small Molecule
Chemical Formula
C15H22FN3O6
CAS Number
154361-50-9
Unique Ingredient Identifier
6804DJ8Z9U
Background

Capecitabine is an orally-administered chemotherapeutic agent used in the treatment of metastatic breast and colorectal cancers. Capecitabine is a prodrug, that is enzymatically converted to fluorouracil (antimetabolite) in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.

Indication

Capecitabine is indicated as treatment for a variety of cancer types. For colorectal cancer, capecitabine is indicated as a single agent or a component of a combination chemotherapy regiment for the adjuvant treatment of stage III colon cancer and treatment unresectable or metastatic colorectal cancer. It can also be used as a part of a combination chemother...

Associated Conditions
Advanced or Metastatic Breast Cancer, Carcinoma of Gallbladder, Cholangiocarcinoma, Hepatocellular Carcinoma, Locally Advanced Rectal Cancer (LARC), Metastatic Adenocarcinoma of the Gastroesophageal Junction, Metastatic Gastric Cancers, Metastatic Neuroendocrine Tumors, Pancreatic Adenocarcinoma, Pancreatic Cancer, Advanced or Metastatic, Platinum-resistant Epithelial Ovarian Cancer, Refractory Fallopian Tube Carcinoma, Stage III Colon Cancer, Unresectable or Metastatic Colorectal Cancer, Metastatic pancreatic endocrine carcinoma, Refractory peritoneal cancer, Refractory, metastatic Colorectal carcinoma, Unresectable, metastatic Esophageal Cancer, Unresectable, metastatic Gastric Cancer, Unresectable, metastatic Gastroesophageal Junction Cancer
Associated Therapies
Chemotherapy

Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer

First Posted Date
2024-02-20
Last Posted Date
2024-02-20
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
302
Registration Number
NCT06268652
Locations
🇨🇳

Yanxia Shi, Guangzhou, None Selected, China

The Efficacy and Safety of Short-course Radiation Combined With Adebrelimab and CAPEOX Neo-adjuvant Therapy for Organ-retention in Patients With MSS/pMMR Ultra Low Rectal Adenocarcinoma

First Posted Date
2024-02-20
Last Posted Date
2024-02-20
Lead Sponsor
Sir Run Run Shaw Hospital
Target Recruit Count
30
Registration Number
NCT06266832
Locations
🇨🇳

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China

A Study to Investigate the Efficacy and Safety of ONO-4578 in Combination With Nivolumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)

First Posted Date
2024-02-13
Last Posted Date
2024-07-29
Lead Sponsor
Ono Pharmaceutical Co. Ltd
Target Recruit Count
210
Registration Number
NCT06256328
Locations
🇰🇷

Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, Korea, Republic of

🇰🇷

CHA Bundang Medical Center, CHA University, Seongnam-si, Gyeonggi-do, Korea, Republic of

🇰🇷

The Catholic University of Korea, St. Vincent's Hospital, Suwon-si, Gyeonggi-do, Korea, Republic of

and more 60 locations

A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.

First Posted Date
2024-02-08
Last Posted Date
2024-11-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
58
Registration Number
NCT06247995
Locations
🇪🇸

Novartis Investigative Site, Barcelona, Catalunya, Spain

The Therapeutic Effect of Different Doses of Capecitabine

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2024-02-07
Last Posted Date
2024-02-07
Lead Sponsor
Jingjiang People's Hospital
Target Recruit Count
150
Registration Number
NCT06246461
Locations
🇨🇳

Clinical effect analysis of different regimens of capecitabine in the treatment of patients with advanced colon cancer, Jingjiang, Jiangsu, China

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC

First Posted Date
2024-02-07
Last Posted Date
2024-05-08
Lead Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Target Recruit Count
30
Registration Number
NCT06245889
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

Reduced-dose Radiotherapy for Stage III Nasopharyngeal Carcinoma Based on the Treatment Response

First Posted Date
2024-02-02
Last Posted Date
2024-04-26
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
593
Registration Number
NCT06239727
Locations
🇨🇳

Zhongshan city Peaple's Hospital, Zhongshan, Guangdong, China

🇨🇳

Union Hospital Affiliated with Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, China

🇨🇳

Xiangya Hospital Central South University, Changsha, Hunan, China

and more 5 locations

The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC).

First Posted Date
2024-01-22
Last Posted Date
2024-02-28
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
100
Registration Number
NCT06217185
Locations
🇨🇳

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China

Neoadjuvant Chemoradiation With Nal-IRI and Capecitabine Guided by UGT1A1 Status in Patients With Rectal Cancer

First Posted Date
2024-01-18
Last Posted Date
2024-08-15
Lead Sponsor
Hebei Medical University Fourth Hospital
Target Recruit Count
60
Registration Number
NCT06210971
Locations
🇨🇳

Hebei Medical University Fourth Hospital, Shijiazhuang, Hebei, China

© Copyright 2024. All Rights Reserved by MedPath